An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method.
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2013
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ENCORE
- 03 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2010 New trial record